UGISense is a biotech startup founded in 2016 with the slogan "Advancing the frontiers of antisense therapy through groundbreaking innovation and strategic collaboration." Specializing in biotechnology, the company is dedicated to developing innovative antisense therapeutic agents by partnering with industry and academic collaborators. Their proprietary platform technology, UgimeresTM, sets them apart in the field. UGISense has secured funding from private investors and has been accredited by the Federal Office of Economics and Export Control (BAFA) under the Funds for Venture Capital program.
With its last investment made in a funding round on 18 June 2018, UGISense continues to attract attention and investment interest within the biotech sector. The company's commitment to innovation and strategic collaboration positions it favorably for future growth and success in the burgeoning field of antisense therapy.
